Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in <scp>DAYBREAK</scp> Trial Participants

20260 citationsJournal Articlegold Open Access

Authors

Ralf Gold · St. Josef-Hospital

Krzysztof Selmaj · Medical University of Lodz

Regina Berkovich · Neurology Center of Southern California

Jeffrey A. Cohen · Cleveland Clinic

G. Comi · Vita-Salute San Raffaele University

Eva Havrdová · Charles University

James K. Sheffield ·

Abstract

Most participants did not relapse within 90 days following ozanimod discontinuation. Post-treatment relapse cases suggestive of a rebound effect were not observed.

Topics & Keywords

Multiple Sclerosis Research Studies Carcinogens and Genotoxicity Assessment Circadian rhythm and melatonin

Publication Details

Published in: Annals of Clinical and Translational Neurology

DOI: 10.1002/acn3.70366

Field-Weighted Citation Impact: 0.00

Command Palette

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in <scp>DAYBREAK</scp> Trial Participants

Authors

Abstract

Topics & Keywords

Publication Details